

**Study of Different Anti-emetic Regimens to Improve
The Control of Nausea and Vomiting in Patients
Receiving Chemotherapy**

Thesis

Submitted to Faculty of Pharmacy

Ain Shams University

In Fulfillment Of The Requirements For the Degree of Master in
Pharmaceutical Sciences
(Clinical Pharmacy)

By the Pharmacist

Ghadir Sultan Amin Alqershi

B.Pharm .Sci, Sana'a University
Republic of Yemen

Supervised by

Dr. Manal Hamed EL-Hamamsy

Assistant professor of Clinical Pharmacy Faculty Of Pharmacy
Ain shams University

Dr. Mohammed Abdulmooti samra

Assistant Professor Of Medical Oncology
National Cancer Institute
Cairo University

Faculty of Pharmacy
Ain Shams University

2013

Acknowledgment

I am so grateful to ALLAH who allowed me to fulfill this thesis. I thank ALLAH so much for giving me people as my family, my friends, my professors and others helped me a lot along the way.

I wish to express my sincere indebtedness and appreciation to Dr. Manal Al-Hamamsy , Assistant Professor of Clinical Pharmacy, Faculty of Pharmacy ,Ain Shams University, as she faithfully supervised my work ,continuously offered encouragement and help ,and revised the manuscript many times .

My deep gratitude and appreciation are to DR. Mohammed Abdulmooti Samra, Assistant Professor of Medical Oncology, National Cancer Institute, Cairo University, for his valuable help, encouragement, and cooperation.

I am also deeply grateful to Prof. Osama Badary, Head of Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University for his encouragement and support.

Also grateful to all my colleagues in Clinical Pharmacy Department, Faculty of Pharmacy , Ain Shams University, and in National Cancer Institute ,Cairo University for their support and help.

Sincere gratitude and appreciation are to all member of my family especially my mother who cared a lot about me, my raising and my education also to my father, who, though not with us his body is found among us by his Soul , and I want to thank my friend Nada Tawfiq that helped me with all managed from the effort and encourage it

may have my full appreciation and gratitude.

My deepest thanks are to my husband, Dr. Ehab Alqershi the best husband in the whole world, for always encouraging me and providing me with everything he can to help in getting this thesis done, I appreciate it so much and I am so grateful to him.

Last but not least I would like to offer all the states of thanks and appreciation and gratitude to my country Yemen, which I hope we can contribute to the renaissance and prosperity.

بسم الله الرحمن الرحيم

Abbreviations

CINV	Chemotherapy Induced Nausea and Vomiting
HEC	High Emetogenic Chemotherapy
MEC	Moderate Emetogenic Chemotherapy
NCI	National Cancer Institute
NCCN	National Comprehensive Cancer Network
ASCO	American Society of Clinical Oncology
MASCC	Multinational Association of Supportive Care in Cancer
5-HT3-RA	5-Hydroxytryptamine Type3- Receptor Antagonist
NK1	Neurokinin 1 receptors
CTZ	Chemoreceptor Trigger Zone
FLIE	The Functional Living Index-Emesis
QoL	Quality of Life
BID	Twice Daily
TID	Three Times Daily
QID	Four Times Daily
OD	Once Daily

List of Tables

No.	Title	Page
1	Relative Emetogenic Potential of Anti neoplastic Agents	34
2	Dosage and administration schedules of antiemetic agents for acute emesis for chemotherapy of high emetic risk	41
3	Recommended Antiemetics and Adult Dosing for Prevention and Treatment of CINV	44
4	Antiemetic Sites of Action and Major Side Effects	45
5	Antiemetic Therapy for Acute Chemotherapy-induced Nausea and Vomiting	46
6	Antiemetic Therapy for Delayed Nausea and Vomiting 24 Hours Post chemotherapy	47
7	Guidelines of MASCC,NCCN , and ASCO	48
8	Dairy card to record demographic data and severity of nausea and vomiting	52
9	Functional Living Index – Emesis	54
10	Demographic data of the studied groups	60
11	Types of malignancy in Group I, Group II, Group III	61
12	Types of chemotherapy administered to patients in Group I, Group II, Group III	62
13	Degree of acute and delayed nausea in Group I, Group II, Group III	64
14	Degree of acute and delayed vomiting in Group I, Group II, Group III	65
15	Summary of Functional Living Index-Emesis (FLIE) interpretation (0-120)	66
16	Percentage of patients reporting no impact of CINV on daily life on individual items of the FLIE in Group I, Group II and Group III	67
17	Response rates over the whole study period (days 1-5 after chemotherapy).	69

Lists of Figures

No.	Title	Page
1	Responsible Neurotransmission Pathways for CINV	42
2	Pattern of CINV	43
3	Visual analog scale	55

Index

Subject

Page

Abstract	1
Introduction and Aim of the work.....	4
Review of literature	8
1. CINV	8
2. Agents used in cancer chemotherapy	9
• Antimetabolites	9
- Fluorouracil	9
- Oral fluoropyrimidines	10
• Cytidine analogs	11
- Cytarabine	11
- Gemcitabine	11
- Azacytidine	12
• Purines and purine antimetabolites	12
- 6-Mercaptopurine and 6-Thioguanine	12
- Fludarabine Monophosphate	13
- Cladribine	13
• Antifolate	13
- Methotrexate	14
- Pemetrexed	15
• Microtubule – targeting drugs	15
- Vinca alkaloids.....	15
• Taxanes	16
• Estramustine	16
• Topoisomerase inhibitors	17

• Anthracycline derivatives	18
- Doxorubicin, Daunorubicin, Idarubicin, Epirubicin	19
- Mitoxantrone	20
• Alkylating agents	20
• Cyclophosphamide and Ifosfamide	21
• Nitrosoureas	21
• Nonclassic alkylating agents	22
- Dacarbazine and Temozolomide	22
• Heavy metal compounds	23
- Cisplatin, Carboplatin, and Oxaliplatin	23
• Miscellaneous agents	25
- Bleomycin	25
- Hydroxyurea	25
- L-Asparaginase	26
- Arsenic trioxide	26
- Mitomycin C	26
• Immune therapies	26
3. Pathophysiology of chemotherapy-induced emesis	28
4. Pattern of CINV	30
- Acute nausea and vomiting	30
- Delayed emesis	31
- Anticipatory emesis	32
5. prevention of CINV	35
• Highly emetogenic chemotherapy	35
- Acute CINV	35
- Delayed CINV	35
• Moderately Emetogenic Chemotherapy	35

- Acute CINV	35
- Delayed CINV	35
• Minimally Emetogenic Chemotherapy	36
6. Management of Breakthrough And Refractory CINV	36
7. Antiemetic Agents	36
- 5-HT3-RAs	36
- Steroids, Dexamethasone	38
- NKIRAs	38
- Metoclopramide	39
8. Other Antiemetic	39
- Benzodiazepines	39
- Antihistamines	40
- Olanzapine	40
Patients and methods	50
Results	57
Discussion	70
Summary and conclusion	75
Recommendations	81
References	82
Arabic summary	

Abstract

Abstract

Background: Chemotherapy-induced nausea and vomiting (CINV) is still one of the most feared side effects of chemotherapy. With the correct use of antiemetic, CINV can be prevented in almost 70% to up to 80% of patients. Treatment guidelines are useful tools that enable physicians to integrate the latest clinical research into their practices. However, there is evidence that adherence to and implementations of treatment recommendations are less than optimal, Uncontrolled CINV can lead to reduced quality of life.

Objective : To study different anti-emetic regimens to improve the control of nausea & vomiting in patients receiving chemotherapy ,and compare the impact of acute nausea and vomiting (during the first 24 hours post chemotherapy) and delayed nausea and vomiting (day 2 through 5days post chemotherapy) on patients' quality of life (QoL) after highly or moderately emetogenic chemotherapy.

Patients and Methods: The current study was prospective, intervention, randomized study; it was carried out at the Outpatient Clinic of Medical-Oncology Department Medical Oncology Department of National Cancer Institute (NCI) Cairo, during the period of Aug 2009 to Feb 2010.

A total of 66 Patients were categorized into three groups: group I (control group): This group included 27 patients 6 males and 21 females, they received their chemotherapy and the conventional antiemetic regimen, as following: Pre chemotherapy Ondansetron 8mg IV, ranitidine 50mg IV and dexamethasone 8mg IV (first day) and ranitidine 150 mg PO and domperidone 10mg PO were bid for seven days post chemotherapy. group II (interventional group): This group included 31 patients; 7 males and 24 females, they received their chemotherapy and antiemetic regimen, as following: before chemotherapy ondansetron 8mg

IV, ranitidine 50 mg IV and dexamethasone 8mg IV. After 12h of chemotherapy they received metoclopramide 20mg IV and dexamethasone 8m IV (first day), and in the second day metoclopramide 20mg PO and dexamethasone 8mg IV were bid for three days. group III (interventional group), this group included 8 female patients, they received their chemotherapy and antiemetic regimen, as following: before chemotherapy ondansetron 8mg IV, ranitidine 50 mg IV and dexamethasone 8mg IV. After 12h of chemotherapy they received ondansetron 8 mg IV, and dexamethasone 8mg IV (first day), in the second day ondansetron 8mg IV and dexamethasone 8mg IV were bid for three days. Patients recorded episodes of nausea and vomiting in a diary. Patients completed the Functional Living Index-Emesis (FLIE) questionnaire on day 5.

Results: for the comparison between different antiemetic regimen to improve control of nausea and vomiting there is highly statistically significant differences between group I, group II and group III, in acute phase: Nausea among group I (n=27), 48.1% are severe; 18.5% are moderate; 14.8% are mild and 18.5% are none; while among group II (n=31), 3.2% are mild and 96.7% are none, and 100% none in group III. And in delayed phase: Nausea among group I (n=27), 35.1% are severe; 26.8% are moderate; 8.3% are mild and 29.6% are none; while among group II and group III 100% none. Also there is high significant differences between group I, group II and group III, in acute phase: Vomiting among group I (n=27), 40.7% are severe; 11.1% are moderate; 29.6% are mild and 18.5% are none; while among group II (n=31), 3.2% are mild and 96.7% are none and 100% none in group III (n=8). And in delayed phase: Vomiting among group I (n=27), 25 % are severe; 22.3% are moderate; 16.7% are mild and 37.9% are none; while among group II (n=31), 3.2% are mild and 96.7% are none and 100% none in group III

(n=8). We found that 59.9% of patients of group I CINV impact on their lives, as well as 63.9% from the same group been affected by nausea and 48.1% of them been affected by vomiting, the high significant differences between group I, group II and group III in reporting no impact of CINV. Also there is highly significant differences between studies groups in different phases of response rate (complete response and no nausea), which group II and group III show a complete response and no nausea.

Conclusion: Regimen of antiemetic containing metoclopramide and dexamethasone is more control on CINV and reduced the impact of CINV on quality of life of patients.

Introduction
and
Aim of the work